Cardiovascular Systems’ (CSI) Predator 360° prospective single-centre clinical study has demonstrated beneficial long-term durability of the Predator 360 PAD system in treating peripheral arterial disease (PAD), or blockages in leg arteries.

Predator 360 PAD systems are percutaneous orbital atherectomy systems indicated for use as therapy in patients with occlusive atherosclerotic disease in peripheral arteries and stenotic material from artificial arteriovenous dialysis fistulae.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The study enrolled 46 patients, who underwent primary intervention with the Predator 360° orbital technology followed by adjunctive balloon inflations if necessary, as assisted by the physician.

Treatment with Predator 360° showed a low (10.9%) reintervention rate within 12 months, compared to 40 to 74% of dissection rates for balloon angioplasty.

Principal investigator of the study Dr. Prakash Makam said 12-month data shows the Predator 360° is a durable solution, resulting in modified lesion compliance, and its unique orbital mechanism of action with differential sanding safely removes resistant plaque, reducing the need for high-pressure balloon inflation and stenting.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
HemoSonics has won the 2025 Marketing Award for its impactful promotion of theQuantra Hemostasis System and leadership in blood management education. See how targeted campaigns, thought leadership content, and hands on clinician training are accelerating Quantra’s market traction and shaping the future of hemostasis testing.

Discover the Impact